stocks logo

COLL

Collegium Pharmaceutical Inc
$
31.780
-0.33(-1.028%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
32.385
Open
32.200
VWAP
31.93
Vol
209.08K
Mkt Cap
1.02B
Low
31.640
Amount
6.68M
EV/EBITDA(TTM)
4.72
Total Shares
32.72M
EV
1.67B
EV/OCF(TTM)
8.43
P/S(TTM)
1.86
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
182.26M
+25.46%
1.883
+16.2%
189.13M
+18.73%
2.042
+26.86%
194.86M
+7.1%
2.190
+23.73%
Estimates Revision
The market is revising Upward the revenue expectations for Collegium Pharmaceutical, Inc. (COLL) for FY2025, with the revenue forecasts being adjusted by 0.24% over the past three months. During the same period, the stock price has changed by 18.27%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.24%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+13.22%
In Past 3 Month
Stock Price
Go Up
up Image
+18.27%
In Past 3 Month
3 Analyst Rating
up Image
30.59% Upside
Wall Street analysts forecast COLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COLL is 41.50 USD with a low forecast of 37.00 USD and a high forecast of 46.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
up Image
30.59% Upside
Current: 31.780
sliders
Low
37.00
Averages
41.50
High
46.00
Piper Sandler
Overweight
maintain
$36 -> $37
2025-05-09
Reason
Piper Sandler raised the firm's price target on Collegium Pharmaceutical to $37 from $36 owing to slightly higher estimates for the legacy pain management business, while keeping an Overweight rating on the shares. The firm notes Collegium reported Q1 adjusted diluted EPS of $1.49 on revenue of $177.8M, compared to consensus of $1.43 and $172.0M, respectively. Guidance for 2025 was unchanged.
Needham
Serge Belanger
Strong Buy
Reiterates
$46
2025-04-09
Reason
HC Wainwright & Co.
Oren Livnat
Strong Buy
Reiterates
$50
2025-03-24
Reason
Piper Sandler
David Amsellem
Hold
Maintains
$37 → $36
2025-02-04
Reason
HC Wainwright & Co.
Oren Livnat
Strong Buy
Reiterates
$50
2025-01-10
Reason
Needham
Serge Belanger
Hold
to
Strong Buy
Upgrades
$46
2025-01-10
Reason
Needham upgraded Collegium Pharmaceutical to Buy from Hold with a $46 price target. The analyst cites the company's topline and adjusted EBITDA 2025 guidance coming in above the firm's and consensus estimates. The firm also believes that the stock's current valuation fails to reflect Collegium's top-line growth, profitability and cash-flow generation, all of which have been enhanced by the addition of Jornay PM and its expected $135M top-line contribution while noting that the continued growth and duration of the pain portfolio remain underappreciated.

Valuation Metrics

The current forward P/E ratio for Collegium Pharmaceutical Inc (COLL.O) is 4.16, compared to its 5-year average forward P/E of 4.65. For a more detailed relative valuation and DCF analysis to assess Collegium Pharmaceutical Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
4.65
Current PE
4.16
Overvalued PE
5.67
Undervalued PE
3.64

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
4.05
Current EV/EBITDA
4.09
Overvalued EV/EBITDA
4.79
Undervalued EV/EBITDA
3.30

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
1.63
Current PS
1.38
Overvalued PS
2.04
Undervalued PS
1.23

Financials

Annual
Quarterly
FY2025Q1
YoY :
+22.66%
177.76M
Total Revenue
FY2025Q1
YoY :
-55.15%
22.19M
Operating Profit
FY2025Q1
YoY :
-91.28%
2.42M
Net Income after Tax
FY2025Q1
YoY :
-90.14%
0.07
EPS - Diluted
FY2025Q1
YoY :
-11.03%
54.60M
Free Cash Flow
FY2025Q1
YoY :
-13.25%
54.75
Gross Profit Margin - %
FY2025Q1
YoY :
-45.57%
29.59
FCF Margin - %
FY2025Q1
YoY :
-92.89%
1.36
Net Margin - %
FY2025Q1
10.30
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
202.2K
USD
1
3-6
Months
4.4M
USD
15
6-9
Months
908.6K
USD
1
0-12
Months
1.1M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
650.0K
Volume
Months
6-9
1
1.1M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

COLL News & Events

Events Timeline

2025-07-07 (ET)
2025-07-07
08:06:47
Collegium Pharmaceutical board authorizes $150M share repurchase program
select
2025-05-12 (ET)
2025-05-12
08:24:28
Collegium Pharmaceutical announces $25M accelerated share repurchase program
select
2025-05-08 (ET)
2025-05-08
16:08:18
Collegium Pharmaceutical backs FY25 revenue view $735M-$750M, consensus $742.47M
select
Sign Up For More Events

News

2.0
07-07NASDAQ.COM
Collegium Pharmaceutical Breaks Above 200-Day Moving Average - Bullish for COLL
8.0
07-07NASDAQ.COM
Collegium Pharma Launches Up To $150 Mln Buyback Program; Stock Up In Pre-market
3.5
06-18Newsfilter
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
Sign Up For More News

FAQ

arrow icon

What is Collegium Pharmaceutical Inc (COLL) stock price today?

The current price of COLL is 31.78 USD — it has decreased -1.03 % in the last trading day.

arrow icon

What is Collegium Pharmaceutical Inc (COLL)'s business?

arrow icon

What is the price predicton of COLL Stock?

arrow icon

What is Collegium Pharmaceutical Inc (COLL)'s revenue for the last quarter?

arrow icon

What is Collegium Pharmaceutical Inc (COLL)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Collegium Pharmaceutical Inc (COLL)'s fundamentals?

arrow icon

How many employees does Collegium Pharmaceutical Inc (COLL). have?

arrow icon

What is Collegium Pharmaceutical Inc (COLL) market cap?